HK Stock Market Move | KINTOR PHARMA-B(09939) rose by more than 13%. It is expected that this month the key data results of the domestic Phase IIb/III clinical trial of KX-826 will be announced.

KINTOR PHARMA-B (09939) surged more than 13%, with the stock price gaining nearly 20% in the past two days. As of the time of writing, it was up 13.33% at HK $2.89, with a trading volume of 19.3898 million Hong Kong dollars. On the news front, regarding the Phase III results of KX-826, an official response from Kintor Pharmaceutical on the investment platform stated that the pre-end-of-phase-III work is progressing smoothly according to plan, and the top-line data results of Phase III are expected to be announced in mid-to-late March. Previously, Sinopharm Intelligence pointed out that Kintor Pharmaceutical will announce the key data results of the domestic Phase IIb/III clinical trial of KX-826 for the treatment of male androgenetic alopecia (AGA) in March this year. In July 2025, the company announced that the Phase II trial had reached its clinical endpoint, with data showing efficacy and good safety. Sinopharm Intelligence believes that KX-826 has the potential in the domestic market, and the announcement of key data results, successful commercialization, or licensing for commercialization in overseas regions will serve as a catalyst for the company's valuation.